Oxford Cancer Biomarkers Ltd (OCB), a leader in AI driven, precision cancer diagnostics, has successfully closed its latest investment round.

Plutus Investment Group LLP led the round, with participation from new and existing investors including UK-based VC funds Esperante Ventures, Longwall Ventures and Panacea Innovation, alongside entrepreneur and professional investor, Mr BK Lee.

Funds will be used to drive UK commercialisation of OncoProg® and ToxNav®, position the products for launch in major global markets through strategic partnerships and advance the development of pipeline products in digital pathology and pharmacogenomics.

Plutus Investments Group LLP is a multi-family office backing entrepreneurs in Europe and the USA, focused on Life Sciences, Biotech, Fintech and Tech investments.

Mohammed Jamal, CEO of Plutus said “We are very excited to be part of the OCB adventure, and very proud to be working with such a skilled team and be leaders in Precision Medicine”.

About Oxford Cancer Biomarkers Ltd (OCB)

Oxford Cancer Biomarkers (OCB) is a spin-out from the University of Oxford, developing and commercialising a suite of AI-enabled diagnostic tools that harness the analytical capabilities of digital pathology and pharmacogenomic markers to optimise cancer treatment pathways. OCB continues to expand its portfolio with novel biomarkers and proprietary algorithms that enable clinicians to make personalised treatment recommendations based on real-world evidence and empower patients to make better-informed decisions about their own cancer therapy.

For more information, please visit www.oxfordbio.com

ENDS

For further information please contact: Oxford Cancer Biomarkers Ltd Tel: +44 1865 784743

Nadia Whittley, CEO: Nadia.Whittley@oxfordbio.com